Sanofi (SNY)
(Delayed Data from NSDQ)
$56.26 USD
-0.07 (-0.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.24 -0.02 (-0.04%) 5:26 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.26 USD
-0.07 (-0.12%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.24 -0.02 (-0.04%) 5:26 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Zacks News
J&J (JNJ) to Kickstart Q2 Earnings for the Pharma Sector
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on J&J's (JNJ) performance when it reports second-quarter results.
Mylan (MYL) Obtains FDA Approval for Biosimilar of Humira
by Zacks Equity Research
Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.
Top Analyst Reports for Oracle, Abbott & Chevron
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Abbott Laboratories (ABT) and Chevron (CVX).
Glaxo Signs Another Deal to Develop a Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) collaborates with Medicago to develop a vaccine candidate for COVID-19 using Medicago's antigen and Glaxo's adjuvant system.
Regeneron Initiates Studies on Experimental Coronavirus Drug
by Zacks Equity Research
Regeneron (REGN) announces initiation of late-stage studies evaluating REGN-COV2 for the treatment and prevention of COVID-19.
Moderna Shares Lose Momentum After Meteoric Rise: Here's Why
by Zacks Equity Research
The encouraging progress with mRNA-based coronavirus vaccine drives meteoric rise in Moderna's (MRNA) shares. However, a rumored concern leads to correction.
Sanofi/Regeneron's Kevzara Fails in Phase III Coronavirus Study
by Zacks Equity Research
Sanofi (SNY) and Regeneron discontinue U.S.-based phase III coronavirus study on Kevzara following failure to achieve improvement in hospitalized patients with severe COVID-19 patients of statistical significance.
Pharma Stock Roundup: PFE's Coronavirus Vaccine Study, Approvals in Focus
by Kinjel Shah
Pfizer (PFE) releases promising early results from its COVID-19 vaccine study. Several new drug/line extensions get approval in the United States, EU and Japan.
Dr. Reddy's Inks Deal With Two Companies for Coronavirus Drug
by Zacks Equity Research
Dr. Reddy's (RDY) signs agreement with FUJIFILM Toyama Chemical and Global Response Aid for Avigan tablets for the potential treatment of COVID-19.
Sanofi (SNY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Sanofi (SNY) closed at $51.08 in the latest trading session, marking a +0.33% move from the prior day.
3 Stocks to Buy as Companies Speed Up Vaccine Production
by Ritujay Ghosh
Although the FDA is yet to approve a drug or treatment for COVID-19, companies have already started ramping up manufacturing lines to meet global demand if any of the experimental vaccines succeed.
Sanofi (SNY) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Translate Bio Up on Vaccine Agreement Expansion With Sanofi
by Zacks Equity Research
Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.
Company News for Jun 24, 2020
by Zacks Equity Research
Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.
3 Best GARP Stocks to Beat Pandemic-Led Market Inefficiency
by Urmimala Biswas
The unprecedented global health crisis is providing a psychological shock to the investment world.
Sanofi Expands Agreement With Translate Bio for mRNA Vaccines
by Zacks Equity Research
Sanofi (SNY) and Translate Bio expand their tie-up to develop mRNA vaccines for infectious diseases. The companies are already developing a mRNA vaccine candidate to combat COVID-19.
Glaxo's Partner Begins Phase I Study on Coronavirus Vaccine
by Zacks Equity Research
Glaxo (GSK) has several collaborations to make its pandemic adjuvant technology available to partners who are making adjuvanted COVID-19 vaccine candidates.
Regeneron Gets FDA Nod for Dupixent 300 Mg Pre-Filled Pen
by Zacks Equity Research
Regeneron (REGN) wins FDA approval for a 300-mg, single-dose, pre-filled pen for asthma drug, Dupixent.
Novo Nordisk Completes Two Studies on Obesity Candidate
by Zacks Equity Research
Novo Nordisk (NVO) provides data from a monotherapy study and a combination study on AM833.
Mylan Gets Favorable Ruling Against Biogen's Tecfidera Patent
by Zacks Equity Research
Mylan (MYL) wins the district court's decision against Biogen's lead MS drug's patent.
Sanofi (SNY) to Create Dedicated Vaccine Center in France
by Zacks Equity Research
Sanofi (SNY) plans to invest almost $690 billion to develop a new production site and research center in France with both dedicated to vaccines.
FDA Ends Hydroxychloroquine's Emergency Use for Coronavirus
by Kinjel Shah
The FDA said that chloroquine and hydroxychloroquine are unlikely to prove effective in treating COVID-19 as the known benefits outweigh the risks.
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Sanofi (SNY) closed at $50.59, marking a +1.28% move from the previous day.
Mylan & Biocon's Semglee Wins FDA Approval for Diabetes
by Zacks Equity Research
Mylan (MYL) and partner Biocon gains FDA approval for diabetes treatment, Semglee.
Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash
by Zacks Equity Research
Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.